ClinConnect ClinConnect Logo
Search / Trial NCT03529669

Cytosponge™ for Post-Chemoradiation Surveillance of Oesophageal Cancer

Launched by UNIVERSITY OF OXFORD · May 17, 2018

Trial Information

Current as of June 04, 2025

Completed

Keywords

Cancer Oesophageal Cancer Gastrointestinal

ClinConnect Summary

In this feasibility study, we are investigating a novel way to test for remaining or reoccurring oesophageal cancer following chemoradiotherapy. The technique used to test this is called a Cytosponge™. We will be testing the use of the Cytosponge™ to determine completion rate, safety and acceptability of the procedure.

Cytosponge™ is a capsule-sized device which contains an expandable, spherical mesh which is attached to a string. The capsule dissolves in the stomach after swallowing, releasing the sponge which is then retrieved by gently pulling the string after five minutes. As the spong...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Male or female, Age \>/=16 years who
  • 1. have undergone pre-operative CRT as treatment for oesophageal cancer and due to undergo oesophagectomy or
  • 2. have undergone definitive CRT as treatment for oesophageal cancer
  • 2. 4-16 weeks post completion of CRT
  • 3. Dysphagia score 0-2 (Mellow Scale)\*
  • 4. Able to swallow tablets
  • 5. Physiologically fit for endoscopy
  • 6. Written (signed and dated) informed consent
  • 7. The patient is willing and able to comply with the protocol for the duration of the study, and scheduled follow-up visits and examinations.
  • Exclusion Criteria:
  • 1. Known to have oesophageal varices or stricture requiring dilatation of the oesophagus.
  • 2. Unable to temporarily discontinue anticoagulation therapy/medication prior to their procedure\*
  • 3. Oesophageal stent
  • 4. Other psychological, social or medical condition, physical examination finding or a laboratory abnormality that the Investigator considers would make the patient a poor study candidate or could interfere with protocol compliance or the interpretation of study results.
  • Patients on anti-coagulation therapy are eligible for the study as long as they are considered suitable candidates for endoscopic biopsy (follow local hospital procedures for management of patients on anticoagulation due to undergo endoscopy). If temporary discontinuation of anticoagulation is required, this should be after consultation with the patients clinical care team.

About University Of Oxford

The University of Oxford, a prestigious institution renowned for its excellence in research and education, serves as a leading clinical trial sponsor dedicated to advancing medical science and improving patient care. With a rich history of innovation and a multidisciplinary approach, the university leverages its extensive expertise in various fields, including medicine, public health, and biomedical research, to conduct rigorous clinical trials. Collaborating with healthcare professionals, industry partners, and regulatory bodies, the University of Oxford aims to translate groundbreaking research findings into effective therapies and interventions, contributing to the global effort of enhancing health outcomes.

Locations

Cambridge, , United Kingdom

Leicester, , United Kingdom

Oxford, , United Kingdom

Hull, , United Kingdom

Manchester, , United Kingdom

Bodelwyddan, , United Kingdom

Cardiff, , United Kingdom

Southampton, , United Kingdom

Milton Keynes, , United Kingdom

Cambridge, Please Select An Option Below, United Kingdom

Bristol, , United Kingdom

Wirral, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Prof Somnath Mukherjee

Principal Investigator

University of Oxford

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials